Q3 Earnings Estimate for Insulet Issued By Leerink Partnrs

Insulet Corporation (NASDAQ:PODD) – Leerink Partnrs upped their Q3 2025 earnings per share (EPS) estimates for shares of Insulet in a research note issued to investors on Thursday, August 7th. Leerink Partnrs analyst M. Kratky now forecasts that the medical instruments supplier will earn $1.12 per share for the quarter, up from their prior forecast of $1.08. The consensus estimate for Insulet’s current full-year earnings is $3.92 per share.

Other analysts have also recently issued reports about the company. Oppenheimer raised their price target on Insulet from $312.00 to $324.00 and gave the company an “outperform” rating in a report on Friday, May 9th. Raymond James Financial reissued an “outperform” rating and issued a $360.00 price target (up from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Canaccord Genuity Group upped their target price on Insulet from $331.00 to $353.00 and gave the company a “buy” rating in a research note on Friday. Truist Financial started coverage on Insulet in a report on Monday, June 16th. They issued a “buy” rating and a $365.00 price target for the company. Finally, Wells Fargo & Company boosted their price target on Insulet from $330.00 to $350.00 and gave the company an “overweight” rating in a research report on Friday. Two analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $330.71.

Insulet Stock Down 0.7%

Insulet stock opened at $304.84 on Monday. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The stock has a 50 day moving average of $298.72 and a two-hundred day moving average of $283.24. The stock has a market capitalization of $21.45 billion, a price-to-earnings ratio of 92.66, a PEG ratio of 2.66 and a beta of 1.35. Insulet has a twelve month low of $180.31 and a twelve month high of $329.33.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%. The company had revenue of $649.10 million during the quarter, compared to analysts’ expectations of $612.31 million. During the same period last year, the firm earned $0.55 EPS. The firm’s revenue for the quarter was up 32.9% on a year-over-year basis.

Insider Transactions at Insulet

In related news, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the sale, the senior vice president owned 23,180 shares of the company’s stock, valued at approximately $7,382,134.60. This trade represents a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.39% of the company’s stock.

Institutional Trading of Insulet

Institutional investors have recently bought and sold shares of the company. Zions Bancorporation National Association UT acquired a new stake in Insulet during the first quarter valued at $26,000. Larson Financial Group LLC boosted its position in Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 81 shares during the last quarter. Golden State Wealth Management LLC boosted its position in Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 69 shares during the last quarter. SouthState Corp boosted its position in Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 76 shares during the last quarter. Finally, Kozak & Associates Inc. bought a new position in Insulet during the second quarter valued at about $32,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.